Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021

This cross-sectional study examines whether new formulations of brand-name novel drugs were associated with novel drugs’ sales and/or therapeutic value as well as characterizes new formulations’ approval timing relative to the novel drug’s generic approval.

[1]  A. Kesselheim,et al.  Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010–2018 , 2022, Journal of General Internal Medicine.

[2]  M. Ratain,et al.  Combination therapy patents: a new front in evergreening , 2021, Nature Biotechnology.

[3]  A. Kesselheim,et al.  Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based? , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  C. Aiken,et al.  Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis , 2021, Diabetes Therapy.

[5]  A. Kesselheim,et al.  Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997 , 2021, Journal of pharmaceutical policy and practice.

[6]  A. Kesselheim,et al.  Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study , 2020, BMJ.

[7]  A. Kesselheim,et al.  US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate. , 2020, JAMA internal medicine.

[8]  J. Keirsse,et al.  Developing blockbuster drugs: both nature and nurture , 2020, Nature reviews. Drug discovery.

[9]  M. Vaduganathan,et al.  Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries , 2020, JAMA network open.

[10]  D. McCormick,et al.  The Effect Of Veterans Health Administration Coverage On Cost-Related Medication Nonadherence. , 2020, Health affairs.

[11]  Sean R. Dickson.  Effect of Evergreened Reformulations on Medicaid Expenditures and Patient Access from 2008 to 2016. , 2019, Journal of managed care & specialty pharmacy.

[12]  J. Ross,et al.  Generic Drugs in the United States: Policies to Address Pricing and Competition , 2019, Clinical pharmacology and therapeutics.

[13]  A. Kesselheim,et al.  New Drug Formulations and Their Respective Generic Entry Dates. , 2019, Journal of managed care & specialty pharmacy.

[14]  Robin C. Feldman.  May your drug price be evergreen , 2018, Journal of law and the biosciences.

[15]  A. Kesselheim,et al.  Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents , 2018, JAMA.

[16]  Jonathan J. Darrow,et al.  Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Ross,et al.  US drug marketing: how does promotion correspond with health value? , 2017, British Medical Journal.

[18]  J. Ross,et al.  High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis. , 2017, JAMA internal medicine.

[19]  D. Gilchrist.  Patents as a Spur to Subsequent Innovation: Evidence from Pharmaceuticals , 2016 .

[20]  Bradley T. Shapiro.  Estimating the cost of strategic entry delay in pharmaceuticals: The case of Ambien CR , 2016 .

[21]  Michael A. Carrier,et al.  Product Hopping: A New Framework , 2016 .

[22]  Genia Long,et al.  Updated trends in US brand-name and generic drug competition , 2016, Journal of medical economics.

[23]  E. Seoane-Vazquez,et al.  Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals , 2015, PLoS ONE.

[24]  A. Kesselheim,et al.  Variations in time of market exclusivity among top-selling prescription drugs in the United States. , 2015, JAMA internal medicine.

[25]  M. Riedel,et al.  Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: A randomised, double-blind, crossover study (eXtRa) , 2015, Schizophrenia Research.

[26]  A. Kesselheim,et al.  Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. , 2014, The American journal of managed care.

[27]  J. Woodcock,et al.  An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. , 2013, Health affairs.

[28]  T. Khong,et al.  Making medicines evergreen , 2012, BMJ : British Medical Journal.

[29]  B. Sampat,et al.  Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents , 2012, PloS one.

[30]  H. Krumholz,et al.  Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. , 2012, Archives of internal medicine.

[31]  Lisa M. Schwartz,et al.  How the FDA forgot the evidence: the case of donepezil 23 mg , 2012, BMJ : British Medical Journal.

[32]  Bhaven N. Sampat,et al.  Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals , 2011, Journal of health economics.

[33]  G. Gerken,et al.  Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice‐daily tacrolimus‐based regimen to once‐daily tacrolimus extended‐release formulation , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[34]  J. Massaro,et al.  Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. , 2009, Journal of cardiac failure.

[35]  M. Dubinsky,et al.  Effect of medication dosing frequency on adherence in chronic diseases. , 2009, The American journal of managed care.

[36]  Fang Zhang,et al.  Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. , 2008, JAMA.

[37]  A. Fendrick,et al.  Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications , 2008, Journal of General Internal Medicine.

[38]  Glenn Ellison,et al.  Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration , 2007 .

[39]  A. Peterson,et al.  Meta-analysis of trials of interventions to improve medication adherence. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[40]  U. Gottwald-Hostalek,et al.  Management of Hypertension With a Fixed‐Dose (Single‐Pill) Combination of Bisoprolol and Amlodipine , 2017, Clinical pharmacology in drug development.